Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. (4521.T) Financial Performance & Income Statement Overview
Analyze Kaken Pharmaceutical Co., Ltd. (4521.T) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Kaken Pharmaceutical Co., Ltd. (4521.T) Income Statement & Financial Overview
Explore comprehensive income reports for Kaken Pharmaceutical Co., Ltd. 4521.T, broken down by year and quarter.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $18.05B | $24.62B | $33.12B | $18.25B |
| Cost of Revenue | $8.98B | $9.53B | $9.07B | $8.20B |
| Gross Profit | $9.07B | $15.09B | $24.05B | $10.05B |
| Gross Profit Ratio | $0.50 | $0.61 | $0.73 | $0.55 |
| R&D Expenses | $8.17B | $4.58B | $2.98B | $3.00B |
| SG&A Expenses | $5.56B | $4.66B | $4.25B | $4.30B |
| Operating Expenses | $13.72B | $9.25B | $7.22B | $7.30B |
| Total Costs & Expenses | $22.70B | $18.78B | $16.29B | $15.50B |
| Interest Income | $37.00M | $0.00 | $0.00 | $4.00M |
| Interest Expense | $9.00M | $0.00 | $0.00 | $5.00M |
| Depreciation & Amortization | $629.00M | $688.25M | $652.00M | $688.25M |
| EBITDA | -$4.73B | $6.53B | $17.48B | $3.44B |
| EBITDA Ratio | -$0.26 | $0.27 | $0.53 | $0.19 |
| Operating Income | -$4.66B | $5.84B | $16.83B | $2.75B |
| Operating Income Ratio | -$0.26 | $0.24 | $0.51 | $0.15 |
| Other Income/Expenses (Net) | -$1.93B | $945.00M | $35.00M | -$379.00M |
| Income Before Tax | -$6.59B | $6.79B | $16.86B | $2.37B |
| Income Before Tax Ratio | -$0.36 | $0.28 | $0.51 | $0.13 |
| Income Tax Expense | -$1.36B | $1.90B | $4.33B | $617.00M |
| Net Income | -$5.23B | $4.89B | $12.53B | $1.75B |
| Net Income Ratio | -$0.29 | $0.20 | $0.38 | $0.10 |
| EPS | -$133.99 | $129.09 | $330.90 | $46.32 |
| Diluted EPS | -$133.99 | $129.09 | $330.90 | $46.32 |
| Weighted Avg Shares Outstanding | $39.03M | $37.87M | $37.87M | $37.87M |
| Weighted Avg Shares Outstanding (Diluted) | $39.03M | $37.87M | $37.87M | $37.87M |
Over the last four quarters, Kaken Pharmaceutical Co., Ltd.'s revenue moved from $18.25B in Q1 2025 to $18.05B in Q4 2025. Operating income in Q4 2025 was -$4.66B, with a strong operating margin of -26%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Kaken Pharmaceutical Co., Ltd. remained robust at -$4.73B, reflecting operational efficiency. Net income dropped to -$5.23B, with an EPS of -$133.99. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan